<DOC>
	<DOCNO>NCT01819220</DOCNO>
	<brief_summary>Recent study demonstrate RAS inhibitors/calcium channel blocker superior RAS inhibitors/diuretics reduce cardiovascular outcome hypertension . As , RAS inhibitors/calcium channel blocker recommend first line combination treatment hypertension . However , mechanism superior efficacy RAS inhibitors/calcium channel blocker well define . This study compare efficacy RAS inhibitors/calcium channel blocker vs RAS inhibitors/diuretics term glucose tolerance insulin resistance hypertensive patient metabolic syndrome . The primary endpoint RAS inhibitors/calcium channel blocker efficacious reduce 2hour post prandial glucose compare RAS inhibitors/diuretics .</brief_summary>
	<brief_title>Randomized , Open Labeled Clinical Trial Compare Effectiveness Amlodipine/Valsartan v Hydrochlorothiazide/Telmisartan Glucose Tolerance Patients With Hypertension With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine , Valsartan Drug Combination</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Telmisartan , hydrochlorothiazide drug combination</mesh_term>
	<criteria>consent study Male Female ≥ 20 year Patients take less 1 antihypertensive medication take antihypertensive medication . Hypertension define screen visit follow ) : 140mmHg &lt; MSSBP MSDBP &gt; 90mmHg screen Hypertensive patient non diabetic metabolic syndrome enrol . Metabolic syndrome define accord NCEP guideline . ( 3 ) ① Abdominal obesity : Waist circumference M ≥ 90cm , F ≥ 80cm ② Hypertriglyceridaemia : Triglycerides ≥ 150mg/dL ③ Low HDL cholesterol Men : HDL cholesterol ≤ 40mg/dL Women : HDL cholesterol ≤ 50mg/dL ④ Elevated blood pressure ( systolic blood pressure ≥ 130 mmHg diastolic blood pressure ≥ 85 mmHg , current use antihypertensive drug ) ⑤ Impaired fast glucose : fasting plasma glucose ≥ 100 mg/dL Patient take statin medication patient ate statin medication last duration must 3 month . • Women childbearing potential without contraceptive measure ( Pregnant nursing woman Known suspect contraindication : history allergy hypersensitivity History clinically significant allergy include asthma and/or multiple drug allergy Patients take 2 antihypertensive medication Patient take statin medication take statin within 3 month MSSBP &gt; 180 mmHg MSDBP &gt; 110 mmHg time study Evidence secondary form hypertension ) History hypertensive encephalopathy , cerebrovascular accident , transient ischemic attack , myocardial infarction , percutaneous coronary intervention ( PCI ) coronary artery bypass graft surgery ( CABG ) 12 month prior Visit 1 History heart failure Grade II IV accord NYHA classification Concomitant potentially life threaten arrhythmia symptomatic arrhythmia Concomitant unstable angina pectoris Clinically significant valvular heart disease Patients Type 1 Type 2 diabetes mellitus Evidence hepatic disease determine one following : AST ALT value ≥ 3 x UNL , history hepatic encephalopathy , history esophageal varix , history portocaval shunt Evidence renal impairment determine one following : serum creatinine &gt; 2mg/dL , history dialysis , history nephrotic syndrome Protein U/A value 2+ ≤ Serum potassium value &lt; 3.2 &gt; 5.2 mmol/L History malignancy organ system within past 5 year , treat untreated , include leukemia lymphoma , define full protocol Chronic use NSAIDs Use cyclooxygenase2 inhibitor ( COX2 inhibitor Use niacin &gt; 100 mg/d Use loop diuretic Use statin short 3 month Inability discontinue prior antihypertensive drug specify full protocol person directly involved execution protocol Volume depletion base investigator 's clinical judgment use vital sign , skin turgor , moistness mucous membrane , laboratory value Any severe , lifethreatening disease within past five year</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>